CA3202364A1 - Compositions de dsg2 et procedes pour le traitement de la covid-19 - Google Patents

Compositions de dsg2 et procedes pour le traitement de la covid-19

Info

Publication number
CA3202364A1
CA3202364A1 CA3202364A CA3202364A CA3202364A1 CA 3202364 A1 CA3202364 A1 CA 3202364A1 CA 3202364 A CA3202364 A CA 3202364A CA 3202364 A CA3202364 A CA 3202364A CA 3202364 A1 CA3202364 A1 CA 3202364A1
Authority
CA
Canada
Prior art keywords
dsg2
isolated polypeptide
protein
covid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3202364A
Other languages
English (en)
Inventor
Shi Yin Foo
Ryan Edward TYLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvada Therapeutics Inc
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of CA3202364A1 publication Critical patent/CA3202364A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de manière générale des compositions et des procédés de traitement de la COVID-19 par l'administration de compositions de l'invention. Les procédés comprennent également le traitement du syndrome post-COVID-19 et de cardiomyopathies à l'aide des compositions décrites dans la présente invention.
CA3202364A 2020-12-15 2021-12-15 Compositions de dsg2 et procedes pour le traitement de la covid-19 Pending CA3202364A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US63/125,583 2020-12-15
US202163274715P 2021-11-02 2021-11-02
US63/274,715 2021-11-02
PCT/US2021/063433 WO2022132854A1 (fr) 2020-12-15 2021-12-15 Compositions de dsg2 et procédés pour le traitement de la covid-19

Publications (1)

Publication Number Publication Date
CA3202364A1 true CA3202364A1 (fr) 2022-06-23

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3202364A Pending CA3202364A1 (fr) 2020-12-15 2021-12-15 Compositions de dsg2 et procedes pour le traitement de la covid-19

Country Status (9)

Country Link
EP (1) EP4263588A1 (fr)
JP (1) JP2024500250A (fr)
KR (1) KR20230120141A (fr)
AU (1) AU2021400845A1 (fr)
CA (1) CA3202364A1 (fr)
IL (1) IL303444A (fr)
MX (1) MX2023006704A (fr)
TW (1) TW202237634A (fr)
WO (1) WO2022132854A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022382972A1 (en) * 2021-11-02 2024-05-09 Arvada Therapeutics, Inc. Dsg2 compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
WO2008147456A2 (fr) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Systèmes d'administration de médicaments en utilisant des fragments fc

Also Published As

Publication number Publication date
MX2023006704A (es) 2023-06-20
EP4263588A1 (fr) 2023-10-25
IL303444A (en) 2023-08-01
WO2022132854A1 (fr) 2022-06-23
TW202237634A (zh) 2022-10-01
AU2021400845A1 (en) 2023-07-13
KR20230120141A (ko) 2023-08-16
JP2024500250A (ja) 2024-01-05

Similar Documents

Publication Publication Date Title
US9932377B2 (en) Mitochondrial targeting and therapeutic use thereof
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
ES2426352T3 (es) Uso de la endoglucosidasa EndoS para el tratamiento de enfermedades mediadas por la inmunoglobulina G
ES2715710T3 (es) Folistatina en el tratamiento de la distrofía muscular de Duchenne
EA009938B1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
CN109328069B (zh) Il-22在治疗坏死性小肠结肠炎中的用途
JP2019206548A (ja) 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
CN111423502A (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
CA2208016A1 (fr) Peptides cd14 anti-inflammatoires
CA3202364A1 (fr) Compositions de dsg2 et procedes pour le traitement de la covid-19
AU2013344973B2 (en) Compositions and methods for the treatment of ectodermal dysplasia
US10034915B2 (en) Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
JP6073230B2 (ja) Ｎｄ２ペプチドおよび神経疾患の治療方法
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
US10160791B2 (en) Protamine in treatment of neuronal injuries
WO2023081674A1 (fr) Compositions dsg2 et méthodes
KR20240110819A (ko) Dsg2 조성물 및 방법
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
JP2015140322A (ja) 関節リウマチまたはその関連疾患の予防または治療剤
JPWO2018088464A1 (ja) 脳梗塞の治療薬
JPWO2010101192A1 (ja) 関節リウマチまたはその関連疾患の予防または治療剤
JP4256497B2 (ja) 血管炎治療剤
WO2022020544A1 (fr) Méthode de traitement d'une affection inflammatoire
GB2241891A (en) Tumour necrosis factor compositions for treating inflammatory disease